+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fibromyalgia - Pipeline Review, H1 2019

  • ID: 4758516
  • Drug Pipelines
  • March 2019
  • Region: Global
  • 84 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • Aptinyx Inc
  • Astellas Pharma Inc
  • Grunenthal GmbH
  • Intec Pharma Ltd
  • Luye Pharma Group Ltd
  • MORE
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2019

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2019, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights:

This latest pipeline guide Fibromyalgia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 1, 7, 2, 2, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • Aptinyx Inc
  • Astellas Pharma Inc
  • Grunenthal GmbH
  • Intec Pharma Ltd
  • Luye Pharma Group Ltd
  • MORE
Introduction

Report Coverage

Fibromyalgia (Fibromyalgia Syndrome) - Overview

Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development

Abide Therapeutics Inc

Aptinyx Inc

Astellas Pharma Inc

Grunenthal GmbH

Innovative Med Concepts LLC

Intec Pharma Ltd

Jiangsu Hengrui Medicine Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Pfizer Inc

Prismic Pharmaceuticals Inc

Tetra Bio-Pharma Inc

Vitality Biopharma Inc

Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles

(cannabidiol + dronabinol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(celecoxib + famciclovir) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-1069562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

faxeladol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-03012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirtazapine ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-2925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Agonize CB1 and CB2 for Chronic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize CB1 and CB2 for Fibromyalgia and Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Type 1 Diabetes and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products

Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones

Featured News & Press Releases

Feb 12, 2019: Tetra Bio-Pharma provides update on its neuropathic and chronic pain drug development program

Feb 05, 2019: Tetra Bio-Pharma redefines quality standards for pharmaceutical grade cannabis-derived products

Jan 28, 2019: Tetra Bio-Pharma files patent application to protect PPP001

Dec 20, 2018: Tetra successfully completes phase 1 study with vaporized version of PPP001

Dec 03, 2018: Aptinyx reports positive data from interim analysis of exploratory study of NYX-2925 in subjects with fibromyalgia

Nov 01, 2018: Tetra Bio-Pharma obtains Health Canada approval to conduct a phase 1 pharmacokinetic & safety study using vaporized version of PPP001

Oct 02, 2018: EpicGenetics Announces Important Reminders for Fibromyalgia Clinical Trial Eligibility

Sep 14, 2018: Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain

Sep 05, 2018: FDA Approves Clinical Trial of Novel Treatment for Fibromyalgia

Sep 03, 2018: Luye Pharma Group: Voluntary announcement class 1.1 new chemical drug LY03012 approved for clinical trial in China

Jun 19, 2018: Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials

Jun 13, 2018: OWC Pharmaceutical Research Completes Development of Next Generation Orally-Disintegrating Tablet

Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions

Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201, a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Abide Therapeutics Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Astellas Pharma Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Grunenthal GmbH, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Innovative Med Concepts LLC, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Intec Pharma Ltd, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Merck & Co Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Pfizer Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Prismic Pharmaceuticals Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Vitality Biopharma Inc, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2019 (Contd..1), H1 2019

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abide Therapeutics Inc
  • Aptinyx Inc
  • Astellas Pharma Inc
  • Grunenthal GmbH
  • Innovative Med Concepts LLC
  • Intec Pharma Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Luye Pharma Group Ltd
  • Merck & Co Inc
  • Pfizer Inc
  • Prismic Pharmaceuticals Inc
  • Tetra Bio-Pharma Inc
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll